Clinical Trial Update: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for INO-4800 in adults at high risk for SARS-CoV-2 exposure; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Disease
• Coronavirus Infection
• Respiratory Syndrome Coronavirus 2

Drugs mentioned

• INO-4800 (INO-4800)

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-12-20